Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice [0.03%]
Mtarc1缺失通过调节巨噬细胞极化对脂质性肝病的保护作用
Xiaofei Yin,Caroline Bickerton,Bryan MacDonald et al.
Xiaofei Yin et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) spans from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and can progress to cirrhosis or hepatocellular ca...
Genetic Information Enhances a Novel Non-Invasive Steatosis Index and Outperforms Existing Steatosis Indices [0.03%]
遗传信息增强了新型非侵入性肝脂肪变指数并优于现有的脂肪变指数
Yousif Alyousifi,Chinmay Raut,Vincent L Chen et al.
Yousif Alyousifi et al.
Background and aims: Early detection of individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) is important as interventions to reduce steatosis can prevent progression to advanced liver disease...
Breaking Barriers: Equitable Treatment Access Achieves Survival Parity in HCC for People With HIV [0.03%]
打破壁垒：公平的治疗途径使肝癌合并HIV患者的生存率实现平等化
Massimo Iavarone,Eleonora Alimenti,Alessandro Soria
Massimo Iavarone
Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD [0.03%]
评估与脂质代谢紊乱单基因障碍相关的致病变异在特征明显的MASLD患者中的作用
Tae-Hwi Schwantes-An,Marco A Abreu,Brent A Neuschwander-Tetri et al.
Tae-Hwi Schwantes-An et al.
Background and aims: Dyslipidemia is common in patients with MASLD, but the frequency and significance of inherited disorders of dyslipidemia are unclear. We investigated the prevalence and significance of pathogenic vari...
Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC [0.03%]
评估晚期肝细胞癌患者阿特珠单抗联合贝伐珠单抗治疗后使用纳武利尤单抗联合伊匹木单抗的效果
Xin Xiang,Yang Yu
Xin Xiang
Risk of Extrahepatic Cancer for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in the United States Medicare Population [0.03%]
美国退伍军人事务部医疗中心代谢功能障碍相关非酒精性脂肪肝病患者发生局灶性癌症的风险
Yestle Kim,Dominic Nunag,Matthew Davis et al.
Yestle Kim et al.
This retrospective observational cohort study was conducted using 100% Medicare fee-for-service claims data (10/01/2015-12/31/2021) to characterise risk of incident extrahepatic cancer in patients with non-cirrhotic metabolic dysfunction-as...
Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy [0.03%]
性激素与肝脏：对疾病进展和激素治疗的影响
Nora Cazzagon,Martina Gambato,Maurizia Rossana Brunetto et al.
Nora Cazzagon et al.
The liver is central to sex hormone metabolism, and sex hormones in turn modulate hepatic physiology and disease processes. Oestrogens are often protective, while androgens tend to worsen disease progression. The clinical implications of ho...
Reconsidering the Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes [0.03%]
脂肪肝疾病对不良妊娠结局影响的再思考
Rumeng Tang,Dongsen Hu,Lili Zhang
Rumeng Tang
MyWayUp: A Digital Intervention for Alcohol Use Disorder in Patients With Alcohol-Related Liver Disease-Results From an RCT [0.03%]
适用于酒精性肝病患者的饮酒障碍数字干预项目“MyWayUp”——一项随机对照试验的结果分析
Clara Oliveras,Mercè Balcells-Oliveró,Ramón Bataller et al.
Clara Oliveras et al.
Background: Alcohol-related liver disease (ArLD) is a public health concern that requires multidisciplinary interventions. Digital health tools may improve retention in alcohol use disorder (AUD) treatment and enhance hea...